Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Clinical trial NCT05220267 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05220267
- Sponsor
- Sun Yat-sen University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2024-11-13
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.